Ultragenyx Pharmaceutical (RARE) Profit After Tax (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Profit After Tax data on file, last reported at -$185.0 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 22.52% year-over-year to -$185.0 million in Q1 2026; TTM through Mar 2026 was -$608.9 million, a 10.85% decrease from a year earlier, with the FY2025 full-year figure at -$575.0 million, down 1.05% from the prior year.
• Profit After Tax for Q1 2026 stood at -$185.0 million, down from -$128.6 million in the prior quarter.
• Over the last five years, Profit After Tax for RARE reached as high as -$115.0 million in Q2 2025 and fell as low as -$245.1 million in Q3 2022.
• Historically, Profit After Tax has averaged -$155.5 million across 5 years, with a median of -$152.3 million in 2022.
• Across the five-year window, Profit After Tax plunged 235.77% in 2022 and surged 34.87% in 2023, its largest moves.
• Year by year, Profit After Tax stood at -$151.8 million in 2022, then gained by 18.63% to -$123.6 million in 2023, then declined by 7.81% to -$133.2 million in 2024, then grew by 3.49% to -$128.6 million in 2025, then plunged by 43.91% to -$185.0 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$185.0 million in Q1 2026, -$128.6 million in Q4 2025, and -$180.4 million in Q3 2025.